Contact
searchSearch
HMP Global
Login

Myelofibrosis News

News
Evaluating Clinically Meaningful Symptom Benefits and Symptom Change Threshold Among Patients With Myelofibrosis Treated With Momelotinib
02/27/2024

Jordan Kadish

Jordan Kadish
Momelotinib displayed clinically meaningful symptom benefits among patients with myelofibrosis, according to a study that analyzed the appropriateness of the symptom change threshold used in the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials.
Momelotinib displayed clinically meaningful symptom benefits among patients with myelofibrosis, according to a study that analyzed the appropriateness of the symptom change threshold used in the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials.
Momelotinib displayed clinically...
02/27/2024
Oncology
News
Addition of Parsaclisib to Ruxolitinib Decreases Spleen Volume and Improves Symptom Scores Among Patients With Myelofibrosis
02/23/2024

Jordan Kadish

Jordan Kadish
The addition of parsaclisib to ruxolitinib treatment decreased spleen volume, improved symptom scores, and demonstrated acceptable safety among patients with primary or secondary myelofibrosis, according to a phase 2 study.
The addition of parsaclisib to ruxolitinib treatment decreased spleen volume, improved symptom scores, and demonstrated acceptable safety among patients with primary or secondary myelofibrosis, according to a phase 2 study.
The addition of parsaclisib to...
02/23/2024
Oncology
News
Ruxolitinib Strengthens Survival Outcomes Among High-Risk Patients With Myelofibrosis
01/22/2024
Ruxolitinib treatment strengthened survival outcomes among high-risk patients with myelofibrosis, according to findings from a population-based retrospective study.
Ruxolitinib treatment strengthened survival outcomes among high-risk patients with myelofibrosis, according to findings from a population-based retrospective study.
Ruxolitinib treatment...
01/22/2024
Oncology
Conference Coverage
The Potential of Pelabresib Plus Ruxolitinib For Treating Patients With Myelofibrosis: The MANIFEST-2 Study
12/08/2023
A study by Raajit K. Rampal, MD, PhD, and colleagues investigates the effects of pelabresib + ruxolitinib in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.
A study by Raajit K. Rampal, MD, PhD, and colleagues investigates the effects of pelabresib + ruxolitinib in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.
A study by Raajit K. Rampal, MD,...
12/08/2023
Journal of Clinical Pathways
News
FDA Approves Momelotinib for Patients With Anemia and Myelofibrosis
10/27/2023
On September 15, 2023, the FDA approved momelotinib for the treatment of adult patients with myelofibrosis and anemia.
On September 15, 2023, the FDA approved momelotinib for the treatment of adult patients with myelofibrosis and anemia.
On September 15, 2023, the FDA...
10/27/2023
Journal of Clinical Pathways
News
Analysis of Symptom Improvements in Patients With MF Receiving Momelotinib in the SIMPLIFY Studies
09/19/2023
Ruben A. Mesa, DO, and colleagues analyzed changes in total symptom scores and individual symptom scores of patients with myelofibrosis who participated in the SIMPLIFY-1 and SIMPLIFY-2 studies.
Ruben A. Mesa, DO, and colleagues analyzed changes in total symptom scores and individual symptom scores of patients with myelofibrosis who participated in the SIMPLIFY-1 and SIMPLIFY-2 studies.
Ruben A. Mesa, DO, and...
09/19/2023
Journal of Clinical Pathways
News
HCRU and Costs Among Medicare Beneficiaries With Myelofibrosis Receiving Ruxolitinib
08/03/2023
A recent study by Aaron T. Gerds, MD, Cleveland Clinic Taussif Cancer Institute, and colleagues evaluated HCRU, costs, and overall survival for patients with myelofibrosis who receive ruxolitinib treatment.
A recent study by Aaron T. Gerds, MD, Cleveland Clinic Taussif Cancer Institute, and colleagues evaluated HCRU, costs, and overall survival for patients with myelofibrosis who receive ruxolitinib treatment.
A recent study by Aaron T....
08/03/2023
Journal of Clinical Pathways
News
Analysis of Patient-Reported Outcomes of Patients With MF or ET in the MOST Study
04/28/2023
Ellen Ritchie, MD, Weill Cornell Medical College, New York, NY, and colleagues recently analyzed patient-reported outcomes (PROs) in myelofibrosis or essential thrombocythemia for patients who participated in the MOST study to measure symptom...
Ellen Ritchie, MD, Weill Cornell Medical College, New York, NY, and colleagues recently analyzed patient-reported outcomes (PROs) in myelofibrosis or essential thrombocythemia for patients who participated in the MOST study to measure symptom...
Ellen Ritchie, MD, Weill Cornell...
04/28/2023
Journal of Clinical Pathways
News
Patient-Reported Quality of Life Analyses From the Phase 3 Momentum Study Compares Momelotiniob vs Danazol for the Treatment of Myelofibrosis
03/02/2023
A phase 3 study comparing danazol vs momelotinib for the treatment of myelofibrosis (MF) found that momelotinib demonstrated greater improvements in disease-related symptoms, physical function, and health-related quality of life among...
A phase 3 study comparing danazol vs momelotinib for the treatment of myelofibrosis (MF) found that momelotinib demonstrated greater improvements in disease-related symptoms, physical function, and health-related quality of life among...
A phase 3 study comparing...
03/02/2023
Journal of Clinical Pathways
Conference Coverage
Exploring Use of Navitoclax in Conjunction With Ruxolitinib in Patients With MF Who are JAKi-Naïve
01/31/2023
Findings from a recent study indicated that the combination of navitoclax and ruxolitinib for the treatment of primary or secondary MF among patients who were classified as JAKi-naïve provided promising and suggestive evidence of disease...
Findings from a recent study indicated that the combination of navitoclax and ruxolitinib for the treatment of primary or secondary MF among patients who were classified as JAKi-naïve provided promising and suggestive evidence of disease...
Findings from a recent study...
01/31/2023
Journal of Clinical Pathways
JCP September/October 2024 Issue

Current Issue

October 2024
Volume 10
Issue 5
Current Issue
Issue Archive

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use